STOCK TITAN

Medtronic plc - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic plc news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic plc stock.

Medtronic plc (NYSE: MDT) is an American medical device company with its operational and executive headquarters in Minneapolis, Minnesota, and legal headquarters in Dublin, Ireland, following its acquisition of Covidien in 2015. As one of the largest medical-device companies globally, Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases.

The company’s extensive product portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. It markets these products to healthcare institutions and physicians worldwide, with international sales accounting for approximately 50% of its total revenue.

In a recent announcement on April 10, 2024, Medtronic unveiled significant advancements in artificial intelligence (AI) for endoscopic care through the launch of ColonPRO™ software for the GI Genius™ intelligent endoscopy system. This new software improves polyp detection and introduces procedural highlights to enhance physicians' workflow. The company has also entered into a collaboration with Modernizing Medicine® to integrate AI-driven data with electronic health records (EHR).

Medtronic recently reported its financial results for the fourth quarter and fiscal year 2024, showcasing a global revenue of $32.364 billion, a 3.6% increase compared to the previous year. The company's revenue growth was fueled by advancements in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

In addition to its financial performance, Medtronic has made strides in technological innovation. The U.S. FDA approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for chronic pain treatment, demonstrating the company’s commitment to addressing unmet clinical needs and improving patient care through advanced technologies.

Medtronic remains dedicated to its mission of alleviating pain, restoring health, and extending life, driven by a global team of over 95,000 employees across 150 countries. The company continues to leverage its diverse knowledge and insatiable curiosity to deliver innovative solutions that transform lives. For more information, visit Medtronic's official website.

Rhea-AI Summary
Thurgood Marshall College Fund and Medtronic partner to launch the Research & Development Engagement program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
partnership
-
Rhea-AI Summary
Medtronic announces CE Mark approval for its new Simplera™ CGM, featuring a smaller size and improved user experience. The device is integrated with the InPen™ smart insulin pen and provides real-time dosing guidance. Medtronic will launch at the EASD Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
-
Rhea-AI Summary
Medtronic LABS unveils commitment to scale tech-enabled healthcare at Clinton Global Initiative 2023 meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Medtronic Foundation shares 3 ways to transform corporate volunteering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Summary
Medtronic receives CE Mark approval for Inceptiv closed-loop rechargeable spinal cord stimulator
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
Rhea-AI Summary
Medtronic's Symplicity Spyral Renal Denervation System receives positive vote on safety and effectiveness from FDA panel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
Rhea-AI Summary
Medtronic plc confirms participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
-
Rhea-AI Summary
Medtronic reports Q1 revenue of $7.7 billion, a 4.5% increase; raises FY24 organic revenue growth guidance to 4.5%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
-
Rhea-AI Summary
Medtronic plc (NYSE:MDT) has approved an increase in its cash dividend for the second quarter of fiscal year 2024. The quarterly amount will be $0.69 per ordinary share, consistent with the first quarter dividend announcement. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index and has increased its annual dividend payment for the past 46 consecutive years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
dividends earnings
Rhea-AI Summary
Medtronic employees in Minneapolis packed 98,700 meals in just two days as part of the annual volunteering drive. In partnership with Meals From The Heart, Medtronic employees have packed over 3.3M meals, which are distributed to local food shelves.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none

FAQ

What is the current stock price of Medtronic plc (MDT)?

The current stock price of Medtronic plc (MDT) is $81.4 as of December 23, 2024.

What is the market cap of Medtronic plc (MDT)?

The market cap of Medtronic plc (MDT) is approximately 103.5B.

What does Medtronic plc specialize in?

Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases, including pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools.

Where are Medtronic’s headquarters located?

Medtronic’s operational and executive headquarters are in Minneapolis, Minnesota, while its legal headquarters are in Dublin, Ireland, following its acquisition of Covidien in 2015.

How significant are Medtronic’s international sales?

International sales account for roughly 50% of Medtronic’s total revenue.

What recent advancements has Medtronic made in AI for healthcare?

Medtronic recently launched the ColonPRO™ software for the GI Genius™ intelligent endoscopy system, enhancing AI-driven polyp detection and procedural highlights. The company also partnered with Modernizing Medicine® to integrate AI data with EHR systems.

What are Medtronic’s recent financial achievements?

Medtronic reported a global revenue of $32.364 billion for fiscal year 2024, a 3.6% increase from the previous year, driven by growth in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

What new technology has Medtronic introduced for chronic pain treatment?

Medtronic introduced the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS), which the U.S. FDA approved for the treatment of chronic pain.

How many employees does Medtronic have worldwide?

Medtronic has a global team of over 95,000 employees across 150 countries.

What is Medtronic’s mission?

Medtronic's mission is to alleviate pain, restore health, and extend life.

Where can I find more information about Medtronic?

For more information about Medtronic, visit their official website at Medtronic.com.

How does Medtronic approach innovation in healthcare?

Medtronic leverages its diverse knowledge, insatiable curiosity, and commitment to helping those in need to deliver innovative technologies that transform lives, focusing on engineering extraordinary healthcare solutions.

Medtronic plc

NYSE:MDT

MDT Rankings

MDT Stock Data

103.49B
1.28B
0.26%
85.42%
0.79%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GALWAY